Guardian Pharmacy Services (NYSE:GRDN) Releases Earnings Results, Beats Expectations By $0.01 EPS

Guardian Pharmacy Services (NYSE:GRDN) announced its earnings results on Monday. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.01, Manual reports. Guardian Pharmacy Services had a return on equity of 31.73% and a net margin of 2.90%.The business had revenue of $377.43 million during the quarter, compared to analysts’ expectations of $381.16 million. Guardian Pharmacy Services updated its FY 2025 guidance to EPS.

Guardian Pharmacy Services Stock Down 2.2%

Shares of GRDN traded down $0.70 during mid-day trading on Wednesday, hitting $30.55. 80,221 shares of the company’s stock were exchanged, compared to its average volume of 216,835. Guardian Pharmacy Services has a twelve month low of $17.78 and a twelve month high of $37.43. The firm has a fifty day moving average of $26.91 and a two-hundred day moving average of $23.97. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 48.04 and a beta of 0.96.

Institutional Trading of Guardian Pharmacy Services

Several large investors have recently modified their holdings of GRDN. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Guardian Pharmacy Services in the first quarter valued at about $233,000. JPMorgan Chase & Co. boosted its holdings in Guardian Pharmacy Services by 48.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock valued at $128,000 after purchasing an additional 1,956 shares during the period. Legal & General Group Plc grew its position in Guardian Pharmacy Services by 1,783.1% in the 2nd quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock worth $317,000 after purchasing an additional 14,104 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Guardian Pharmacy Services by 121.1% during the 2nd quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock worth $345,000 after purchasing an additional 8,860 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Guardian Pharmacy Services during the second quarter valued at about $214,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Truist Financial raised their price objective on shares of Guardian Pharmacy Services from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 26th. Oppenheimer started coverage on Guardian Pharmacy Services in a report on Friday, October 10th. They issued an “outperform” rating and a $30.00 price target on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Guardian Pharmacy Services in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a report on Sunday. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Guardian Pharmacy Services presently has an average rating of “Moderate Buy” and a consensus target price of $29.33.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.